CAMS keeps a biopharma team’s confirmed messages, primary references, and MLR sign-off history in one place — so every press release, affiliate toolkit, and channel variant carries the exact wording and evidence behind it. Your reviewers still decide. They stop re-reading the same facts from zero.
One connected record from the material you have to every market that needs it. Every screen here is CAMS itself, running the fictional example portfolio that ships with it.
Paste notes, a brief or a transcript, or upload a Word, PowerPoint, text-based PDF or text file. CAMS keeps the original and anchors each proposed message to its page, slide, speaker note or paragraph.
CAMS proposes candidate messages and binds the product named in the source. Your team edits, confirms and arranges them in a message house. Each confirmed reference is pinned to the section cited and a verbatim excerpt.
Prepare an offline email review package today, or submit through Veeva Vault PromoMats once your administrator connects it. The MLR decision is recorded against the exact revision.
Draft a media backgrounder, a short social post and a plain-language patient summary from one saved message. Writers change the voice, length and register; CAMS reads each draft back against the approved wording for meaning, not word matching.
Pin exact versions of the drafts built on your messages into a toolkit for each brand, launch or moment, with each reference’s jurisdiction named. Markets request the toolkit in their language and receive AI-translated drafts for local review.
The voice changes for each audience. The meaning is what every draft is checked against.
“In the Phase 3 ZELVA-2 trial, VELORIX reduced the risk of disease progression or death by 38% compared with chemotherapy in adults with previously treated EGFR-mutated advanced non-small cell lung cancer.”
“In a large study of adults whose advanced EGFR-mutated lung cancer had already been treated, people taking VELORIX were 38% less likely to have their cancer grow or to die than people taking chemotherapy.”
“In the Phase 3 ZELVA-2 trial, VELORIX lowered the risk of disease progression or death by 38% versus chemotherapy in adults with previously treated EGFR-mutated advanced non-small cell lung cancer.”
“Phase 3 ZELVA-2: VELORIX cut the risk of progression or death by 38% vs chemotherapy in previously treated EGFR-mutated advanced NSCLC.”
“En el ensayo de fase 3 ZELVA-2, VELORIX redujo un 38 % el riesgo de progresión de la enfermedad o muerte en comparación con la quimioterapia en adultos con cáncer de pulmón no microcítico avanzado con mutación de EGFR previamente tratado.”
“第3相ZELVA-2試験において、VELORIXは、既治療のEGFR遺伝子変異陽性進行非小細胞肺がんの成人患者で、化学療法と比較して病勢進行または死亡のリスクを38%低下させました。”
one approved message, three audience drafts and two affiliate translations
every version linked to revision 3, its references and the recorded MLR decision
approvals inherited. Every version is a new candidate for your reviewers, and a Preserved result is a review aid, never an approval.
VELORIX and ZELVA-2 are fictional. The drafts and translations are illustrative.
Ready for your reviewers, not instead of them. Nothing is approved by CAMS; every message is traceable to its primary source and recorded MLR decision.
CAMS includes a Vault PromoMats submission path for message review. It reads “Not connected” until your administrator connects it in Settings and it has been exercised in your Vault sandbox. Each submission then keeps its receipt on the record.
Download the review package — exact wording, original files, pinned references and a checksum for every file — with an editable email draft for your agreed review process. Nothing is sent without you.
CAMS has message review only; launch materials and their MLR review live in CommsRx. A package download is not a submission, and a submission is not an approval. US English submission is in scope; affiliates follow their own local business and MLR processes.
In 2005, as a 22-year-old assistant account executive, Abhi spent nights printing clinical papers, highlighting supporting sentences in yellow marker, tabbing three-ring binders, and racing the last FedEx pickup for morning MLR review. Twenty years later — as a global communications executive at the largest healthcare company in the world — the courier was gone, but the friction wasn’t. Whether it was an FDA approval kit, a reactive congress FAQ, or an unbranded disease-awareness post for corporate LinkedIn, teams were still re-proving the same facts from scratch across disconnected Word files inside systems built for marketing throughput.
He built CAMS so the yellow highlight, the primary source, the required qualifications, and the recorded MLR decision live inside the message itself — once — and travel with every adaptation your team creates.
Abhi Basu · Founder, Signal Fidelity Group
Results. At the primary analysis, treatment with zelvoranib reduced the risk of disease progression or death by 38% compared with chemotherapy in previously treated patients. Median follow-up was …
Printed · highlighted · tabbed · couriered overnight for morning review
“In the Phase 3 ZELVA-2 trial, VELORIX reduced the risk of disease progression or death by 38% compared with chemotherapy in adults with previously treated EGFR-mutated advanced non-small cell lung cancer.”
CAMS is the message layer for biopharma communications, from Signal Fidelity Group. It keeps a pharma, biotech or medtech communications team’s confirmed messages, primary references and MLR sign-off history in one place, so the team can adapt each approved message for every audience, channel and market and send every version to review already traced to the wording MLR approved. CAMS proposes; your team confirms; your MLR reviewers approve. Nothing is approved by CAMS.
CAMS is for the people who carry a message from approval to market. Communications leads get one library of confirmed and MLR-approved messages the whole team writes from. Medical, legal and regulatory reviewers get packages that arrive with their sources, pinned references and a record of exactly what changed. Agencies brief and draft from the approved source, not last quarter’s deck. Affiliates and markets get toolkits and translations that start from the approved US message, then follow their local process.
In CAMS the approved message is the fixed point. CAMS lists the figures and qualifiers each version must keep, drafts a media backgrounder, a short social post and a plain-language patient summary from it, and reads each draft back against the approved wording. Each draft carries its result, Preserved, Review or Blocked, to your reviewers. The voice changes for each audience; the approved meaning, which carries the strategy, is what every draft is checked against. None of these results is an approval.
The CAMS wording check reads a draft against the saved meaning of the message it came from and blocks specific failures outright: a reversed negation, a changed or invented number, swapped trial arms. Other differences are marked for a person to read. A Preserved result is a review aid, not an approval, and the check never replaces your reviewers.
Before the decision, label-dependent wording waits in CAMS as a placeholder and is reviewed as such. When the approval letter and the label arrive, your team lifts the exact label wording into the messages, pins each message to its label section, adds the short safety information and the prescribing-information link, and records the MLR decision against that revision. A launch draft written in Word can then be checked against the locked house word for word: CAMS lists the sentences that still carry a placeholder or an earlier saved wording, and any missing safety information or prescribing-information link, with the locked wording to copy. A reworded sentence is not detected, so a person still reads the draft.
No. CAMS prepares work for review. Formal approval stays with your MLR process, in Veeva Vault PromoMats or your offline review. A wording check or a confirmed wording is never treated as an approval.
CAMS accepts Word, PowerPoint, text-based PDF and text files up to 10 MB, or pasted notes, briefs and transcripts. It keeps the original file, reports what it could not read, and anchors each proposed message to its page, slide, speaker note or paragraph.
Start with material that is already public or already approved for this use, or with a fictional example. Confidential or embargoed material, including an approval letter or label before it is announced, waits until written data arrangements with Signal Fidelity Group cover it. CAMS does not claim security certifications it has not earned.
From a message, CAMS searches PubMed, ClinicalTrials.gov and FDA prescribing information with public terms, or you attach a document as data on file. Candidates attach with their original record. A reference counts only when a person pins it to the section cited and a verbatim excerpt; whether it supports the wording is your reviewer’s decision.
No. CAMS prepares every message review package for offline email review, which works from day one. Its Veeva Vault PromoMats connection reads Not connected until your administrator connects it in Settings and it has been exercised in your Vault sandbox; once connected, CAMS can submit the package and keep the receipt. A package download is not a submission, and a submission is not an approval.
Markets can request a CAMS toolkit in their language and receive AI-translated drafts labelled for local review, with the US source beside each one. A message that rests only on the US label carries a note to substitute the EU SmPC or a global publication. Each affiliate reviews its translations through its own local business and MLR process.
CAMS and CommsRx both come from Signal Fidelity Group. CAMS works on its own; CommsRx, the wider communications platform, includes it. A team that starts in CAMS can carry its library into CommsRx as a one-way export, and approvals never transfer.
CAMS was built by Abhi Basu, founder of Signal Fidelity Group. He started in 2005 as an assistant account executive, printing clinical papers, highlighting supporting sentences and tabbing MLR binders by hand, and later worked as a global communications executive at the largest healthcare company in the world. He built CAMS so the highlighted evidence, the primary source, the required qualifications and the recorded MLR decision live inside the message itself and travel with every adaptation.
CAMS stands on its own. When the job widens into strategy, planning and launch materials, your library can be carried into CommsRx as a one-way export. Approvals never transfer.
A 30-minute walkthrough built around your next milestone: a readout, an approval, a congress or a leadership message. If CAMS is not the right tool for the job, you will hear that in the first conversation.
